Creative Medical Technology Holdings heads into the week with short sellers in clear retreat — and the borrow market quietly loosening to match.
Short interest has collapsed over the past month. At 4.1% of the free float, the position is now less than half what it was in early April, when it peaked near 9%. The weekly decline of nearly 15% accelerates a drawdown that began in late March, when shorts had accumulated close to 345,000 shares. By May 7 that figure was down to roughly 151,000. The move suggests a meaningful unwind, not just noise.
The borrow picture reinforces that read. Cost to borrow has dropped sharply from its worst levels — in early April it ran above 50% annualised, a steep premium that made holding short positions expensive. It has since more than halved to around 24.8%, still elevated for a micro-cap biotech but well off the squeeze-risk territory of six weeks ago. Availability has eased too, now at 121% of short interest — meaning roughly 1.2 shares are available to borrow for every one already shorted. That is a notably looser lending pool than a month ago. The ORTEX short score of 64.3 confirms the direction of travel: still above the midpoint, but down from 68-plus readings seen through late April and early April.
The price has tracked the short unwind, moving modestly higher. CELZ closed at $2.31 on May 8, up 3.1% on the week and 2.7% on the month. The gains are measured rather than explosive — there is no sign of a classic squeeze dynamic, just a slow drift upward as short positioning deflates. Peer biotechs showed more dramatic swings: surged 36% on the week and added 23%, while fell 15% and dropped 25%. CELZ's relative steadiness stands out against that backdrop.
One factor score is worth flagging. The EPS surprise rank lands at the 89th percentile — meaning the company has consistently beaten consensus estimates relative to its universe. That is unusually high for a micro-cap biotech with an $8.5 million market cap and no current analyst coverage in this dataset. The next earnings event is scheduled for August 13, giving the data time to develop. Analyst data carries a staleness caveat: the only available price target on record is from June 2025 and has not been updated since, making it an unreliable anchor at current prices.
The institutional base is thin and concentrated. Anson Advisors holds 6.2% of shares, Armistice Capital another 3.7%. Neither reported a change in their last filing. Jane Street and Citadel each added fresh positions as of December 2025, but the absolute share counts are small. Insider activity is stale — the last recorded trade was a director selling less than $5,000 worth of stock in February 2025, too dated to carry weight.
What to watch next is whether the short unwind finds a floor. At 4.1% of the float, short interest is no longer extreme — further covering pressure would need a fresh catalyst to materialise. The August earnings date and any pipeline news from the regenerative medicine programmes are the logical triggers to monitor.
See the live data behind this article on ORTEX.
Open CELZ on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
